Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs. Ysios Capital participates in the round

by Ysios Capital

1 year ago
Xeltis, Ysios Capital, aortic valve, biomaterials

Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C finan...

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

by Ysios Capital

Vivet Therapeutics (‘Vivet’), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in a Series A financ...

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

2 years ago
Ysios Capital, BioClin Therapeutics, Sofinnova Ventures, HealthCap, Life Science Partners, Tekla, Caixa Capital Risc, BioFund II

The financing was led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. Since its founding, ...

OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

2 years ago
OxThera, Oxabact®, Primary hyperoxaluria, Ysios Capital, kidney deterioration, calcification of soft tissues

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If...

CorWave Raises $17.1 Million in Series B Financing

by Ysios Capital

2 years ago
CorWave, Ysios Capital

CorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing share...

Parkinson’s disease: Prexton Therapeutics, participated by Ysios Capital, completes phase 1 clinical trial

by Ysios Capital

2 years ago
Prexton Therapeutics, Ysios Capital, Parkinson’s disease

Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models

CVRx® Secures $113 Million in New Financing

by Ysios Capital

3 years ago
Ysios Capital, CVRx, Barostim Neo

CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completi...

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

3 years ago
X-ALD, Minoryx Therapeutics, MIN-102, Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Stat Diagnostica announces 25 Million Euros in Series C Financing led by Gilde Healthcare

by Ysios Capital

3 years ago
Stat Diagnostica, Gilde Healthcare, Kurma Partners, Boehringer Ingelheim Venture Fund, Ysios Capital, Ysios BioFund I, Caixa Capital Risc, Axis, Idinvest Partners

Led by new investor Gilde Healthcare , the financing round al so drew participation from existing investors , including Kurma Partners ; Ysios Capital ; Idinvest Partners ; Boehringer Ingelheim Ventur...

La Caixa leads an investment round in Inbiomotion with the participation of Ysios Capital

by Professional Newco

3 years ago
Caixa Capital Risc, Caixa Innvierte Biomed II, Ysios Capital, Fundació Vila Casas, Inbiomotion

The fund is driven by ”la Caixa” and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme an...

Aelix Therapeutics completes Series A funding of € 11.5 M ($ 12.7 M)

by Caixa Capital Risc

3 years ago
Caixa Capital Risc, HIVACAT, Ysios Capital, IrsiCaixa, Aelix Therapeutics, Ysios BioFund II Innvierte, Johnson and Johnson Innovation, HTI immunogen

The proceeds will support the development of the HTI immunogen as a therapeutic vaccine against HIV infection, up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individ...

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

3 years ago
orphan diseases, Minoryx Therapeutics, Caixa Capital Risc, Ysios Capital, Ysios BioFund II Innvierte, SEE-Tx, X-ALD, MIN-102, Roche Venture Fund, Kurma Partners, Idinvest Partners, Chiesi Ventures, HealthEquity

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...